Exelixis | EXEL - Interest Expense On Debt


Exelixis reported $23.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2023.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics 349.66M 12.86M Jun/2026
Amgen USD 95.64B 94.98B Jun/2026
AstraZeneca USD 340M 144M Jun/2026
Bayer EUR 675M 87M Dec/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Cytokinetics USD 34.83M 1.5M Jun/2026
Eisai JPY 1.96B 409M Jun/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Genmab DKK 139M 129M Jun/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Incyte USD 582K 13K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026
Pfizer USD 667M 4M Jun/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sanofi EUR -25M 99.78M Dec/2025
Takeda JPY 63.85B 20.2B Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Xencor USD 7.35M 2.65M Jun/2026